中国の医療用画像市場：製品別、用途別、エンドユーザー別、地域別、機会、予測、2017年～2031年

中国の医療用画像の市場規模は、予測期間の2024年～2031年のCAGRが6.02％となり、2023年の33億3,000万米ドルから2031年には53億2,000万米ドルに成長すると予測されています。中国の医療用画像市場は、政府の取り組みや資金提供、慢性疾患の増加と高齢化、技術の進歩、医療アクセスの拡大、デジタルヘルスソリューションの統合、医療意識の高まり、戦略的パートナーシップ、「健康な中国2030」ビジョン、償還政策の改善など、いくつかの要因によって牽引されています。これらの要因が総合的に高度な画像処理技術への需要を高め、アクセス性を向上させ、市場のダイナミックな成長と進化を促しています。

医療用画像は、適切な診断と適切な治療計画に不可欠な詳細な体内画像の生成を可能にするため、医療に不可欠な要素です。これらの技術は、病気の早期発見、病気の進行、治療のモニタリングにおいて重要な役割を果たしています。PET、SPECT、MRIといった様々なモダリティの技術進歩が、医療用画像診断市場を本質的に牽引しています。加えて、医療用画像処理市場の開拓は、医療費の伸びと多数の先進諸国、特に新興経済諸国における画像処理技術の浸透によっても推進されます。

当レポートでは、中国の医療用画像市場について調査し、市場の概要とともに、製品別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 中国の医療用画像市場の見通し、2017年～2031年

• 市場規模の分析と予測
• 市場シェア分析と予測
• 市場マップ分析、2023年
  • 製品別
  • 用途別
  • エンドユーザー別
  • 地域別

第5章 需要供給分析

第6章 輸出入の分析

第7章 バリューチェーン分析

第8章 ポーターのファイブフォース分析

第9章 PESTLE分析

第10章 価格分析

第11章 市場力学

第12章 市場の動向と発展

第13章 規制枠組みとイノベーション

第14章 特許の情勢

第15章 ケーススタディ

第16章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場参入企業トップ10の情勢
  • GE HealthCare Technologies Inc.
  • Koninklijke Philips N.V.
  • Siemens Healthineers AG
  • Shenzhen Mindray Bio-Medical Electronics Co Ltd
  • FUJIFILM Holdings Corporation
  • Hologic Inc.
  • Canon Medical Systems Corporation
  • Shenzhen Anke High-tech Co., Ltd
  • Shanghai United Imaging Healthcare Co., Ltd.
  • Neusoft Medical Systems Co. Ltd.

第17章 戦略的提言

第18章 お問い合わせと免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. China Medical Imaging Market, By Value, In USD Billion, 2017-2031F
• Figure 2. China Medical Imaging Market, By Volume, In Million Units, 2017-2031F
• Figure 3. China Medical Imaging Market Share (%), By Product, 2017-2031F
• Figure 4. China Medical Imaging Market Share (%), By Application, 2017-2031F
• Figure 5. China Medical Imaging Market Share (%), By End-user, 2017-2031F
• Figure 6. China Medical Imaging Market Share (%), By Region, 2017-2031F
• Figure 7. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 8. By Application Size Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 9. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 10. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

China medical imaging market is projected to witness a CAGR of 6.02% during the forecast period 2024-2031, growing from USD 3.33 billion in 2023 to USD 5.32 billion in 2031. Chinese medical imaging market is driven by several factors, which include government initiatives and funding, rising chronic diseases and an aging population, technological advancements, expanded healthcare access, integration of digital health solutions, growing healthcare awareness, strategic partnerships, the 'Healthy China 2030' vision, and improved reimbursement policies. These factors collectively enhance the demand for advanced imaging technologies and improve accessibility, driving the market's dynamic growth and evolution.

Medical imaging is an essential part of health care since it allows the generation of detailed internal images, which are critical for appropriate diagnosis and proper treatment plans. These technologies play a vital role in early disease detection, disease progression, and treatment monitoring. The technological advancements in the various modalities, such as PET, SPECT, MRI essentially drive the medical imaging market. In addition, the development of the medical imaging market is also driven by healthcare expenditure growth and the penetration of imaging technologies in numerous advanced economies, especially in developing countries.

For instance, in April 2023, Shanghai United Imaging Healthcare Co., Ltd., received approval from China National Medical Products Administration (NMPA) for its novel product - Medical Angiography X-ray Machine. This groundbreaking product, featuring computer vision technology, delivers less scanning time with improved workflow and surgical efficiency, significantly impacting the field of medical imaging.

Healthy China 2030's Vision to Support the Growth of China Medical Imaging Market

One of the most important factors driving the medical imaging market growth is the 'Healthy China 2030' vision. This will be the national strategy for public health and medical quality improvement in China. The vision is underpinned by a focus on early diagnosis, prevention, and treatment of diseases- that in turn drives high requirements for sophisticated medical imaging technologies enabling the detection of health conditions precisely and promptly. Focus on enhancing healthcare infrastructure and opening avenues for diagnostics have translated into an uptake in investments towards new-age imaging solutions. Moreover, the emphasis on preventive care and health management as part of 'Healthy China 2030' will further drive demand for comprehensive imaging solutions to enable routine screenings and healthcare assessments.

For instance, in April 2024, Arineta Ltd. (Arineta), a leader in advancing cardiovascular imaging solutions, partnered with Shandong Yituo Medical Technology Development Co. Ltd. (SYMT), a JMC-invested company to form a new joint venture, Arineta (Shandong) Medical Equipment Co. Ltd. This partnership is aimed to expand the market reach of Arineta's SpotLight Duo, a cardio-thoracic CT in China.

Rising Age-Related Chronic Diseases and Ailments Promote Market Growth

One of the primary drivers of increasing demand for medical imaging is notably an ever-increasing occurrence of age-related chronic diseases and disorders. An aging Chinese population rapidly requires early and precise diagnosis of cardiovascular diseases, cancers, neurodegenerative disorders, etc. As a result, sophisticated medical imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT) scans, and positron emission technology (PET) are crucial in monitoring, diagnosing, and treatment of these diseases. Improved diagnostic capability based on the existence of high-resolution imaging and functional imaging techniques with the Individualised treatment strategy. Furthermore, the rising incidence of these diseases requires frequent screening and follow-up, leading to the growing usage of imaging services. According to the World Health Organization (WHO) estimates, in 2019, China had 254 million people aged 60 and over. This number is expected to increase to 402 million by 2040. The data further highlights that, due to increased life expectancy and reduced mortality rates, the proportion of people aged 60 and over is expected to reach 28% by 2040. This demographic shift underscores the growing need for advanced medical imaging solutions to effectively manage and diagnose age-related conditions.

Oncology Segment Leads China Medical Imaging Market Share

Oncology is one of the key contributors to the China imaging market, supported by high cases of cancer that require advanced medical imaging such as PET-CT, MRI and radiography. The Chinese government is investing heavily in healthcare infrastructure, which supports the adoption of advanced imaging technologies. In addition, the recovery of the oncology market is fueling demand for state-of-the-art imaging systems in specialized cancer centers. Patient demand for routine imaging is rising due to greater awareness and emphasis on early detection. Furthermore, heightened public awareness of the significance of timely diagnosis is resulting in more requests for routine imaging prescripts from younger sectors. The growing incidence of cancer among populations underscores this need.

For instance, according to the National Cancer Center Registry, in 2022, China recorded approximately 4,824,700 new cancer cases, of which around 2,903,900 new cases were diagnosed in urban areas, while an estimated 1,920,800 new cases occurred in rural areas.

East China Dominates the China Medical Imaging Market

Several key factors are driving the growth of medical imaging in East China. The densely populated region, which includes major urban centers like Shanghai and Hangzhou, has a high demand for medical imaging services and technological innovations. East China has a well-established medical infrastructure with advanced imaging technology in major hospitals and diagnostic centers. The workflow and financial stability in the region are capable of high expenditure on health services, as well as its penetration for the adoption of new diagnostic imaging modalities. Additionally, the existence of top research organizations and technology firms boosts the medical imaging market on innovation; besides that, significant investments in healthcare infrastructure and technologies by the government as well as from the private sector are strengthening its market growth further. The impact of these, together with other factors, give East China a dominant position in the medical imaging sector. For instance, in May 2024, East China Normal University (ECNU) entered into a strategic research agreement with Shanghai United Imaging Healthcare Co., Ltd. The collaboration is aimed to promote and develop innovative platforms and technology in the field of medical imaging.

Future Market Scenario (2024-2031F)

The diagnostic equipment with artificial intelligence will have a revolutionary impact on the Chinese market because of AI's potential to improve precision and efficiency significantly. Radiologists effectively identify irregularities using AI, as these algorithms can rapidly analyze complex imaging data and draw attention to key pieces. The technology boosts workflow efficiency and reduces diagnostic error - in line with China's drive towards smarter healthcare. In addition, the investment by China in the AI research and development sector, along with governmental efforts to improve healthcare technology, will help develop a conducive environment for the deployment of AI in medical imaging. For instance, on November 7, 2023, NMPA released "Clinical Evaluation Guideline on Artificial Intelligence-assisted Detection Medical Devices (Software)" guidelines with an objective of evaluating and standardize clinical trials for AI-assisted diagnostic products. Moreover, as per the NMPA data, post-COVID-19, there has been an acceleration in the approval of artificial intelligence medical devices (AIMDs). For instance, before 2020, 11 AIMDs were approved, while the number of approved AIMDs increased to 55 in 2020, 101 in 2021, and 89 in 2022.

Key Players Landscape and Outlook

Regulatory approvals and launches, growing expansion and investment in the country by major market players, mergers and acquisitions, and collaborations are the most common market strategies observed in recent times.

In May 2023, Siemens Healthineers AG invested USD 142 million (Yuan 1 billion) in China's research and manufacturing capacity situated in Shenzhen, Guangdong province. This investment is aimed at boosting the company's production and innovation of magnetic resonance systems, angiography systems, and medical electronic components.

In February 2022, Siemens Healthineers AG and Universal Medical Imaging Group of Shanghai Panoramic Medical Imaging Technology Co., Ltd. entered a strategic collaboration to enhance the efficiency of image screening and disease diagnosis in primary healthcare institutions across China. This partnership will leverage advanced imaging diagnostic equipment and remote scanning assistant tools from Siemens Healthineers AG, combined with the expertise of Universal Medical Imaging's nationwide network. The collaboration aims to support medical staff and healthcare providers in delivering more accurate, convenient, and timely diagnostic services, ultimately improving patient access to high-quality care.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. China Medical Imaging Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Product
    • 4.2.1.1. X-ray Devices
      • 4.2.1.1.1. Radiography
      • 4.2.1.1.2. Fluoroscopy
      • 4.2.1.1.3. Mammography
    • 4.2.1.2. Ultrasound
      • 4.2.1.2.1. Handheld
      • 4.2.1.2.2. Compact
    • 4.2.1.3. Computed Tomography (CT)
      • 4.2.1.3.1. High-end Slice CT
      • 4.2.1.3.2. Mid-end Slice CT
      • 4.2.1.3.3. Low-end Slice CT
      • 4.2.1.3.4. Cone Beam CT
    • 4.2.1.4. Magnetic Resonance Imaging (MRI)
      • 4.2.1.4.1. Closed System
      • 4.2.1.4.2. Open System
    • 4.2.1.5. Nuclear Imaging
      • 4.2.1.5.1. SPECT
      • 4.2.1.5.2. PET
  • 4.2.2. By Application
    • 4.2.2.1. Cardiology
    • 4.2.2.2. Oncology
    • 4.2.2.3. Neurology
    • 4.2.2.4. Orthopedics
    • 4.2.2.5. Gastroenterology
    • 4.2.2.6. Gynecology
    • 4.2.2.7. Others
  • 4.2.3. By End-user
    • 4.2.3.1. Hospitals
    • 4.2.3.2. Diagnostic Imaging Centers
    • 4.2.3.3. Others
  • 4.2.4. By Region
    • 4.2.4.1. South
    • 4.2.4.2. East
    • 4.2.4.3. North
    • 4.2.4.4. Northeast
    • 4.2.4.5. Central
    • 4.2.4.6. Southwest
    • 4.2.4.7. Northwest
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Product
  • 4.3.2. By Application
  • 4.3.3. By End-user
  • 4.3.4. By Region

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Regulatory Approvals

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players*
  • 16.3.1. GE HealthCare Technologies Inc.
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 16.3.2. Koninklijke Philips N.V.
  • 16.3.3. Siemens Healthineers AG
  • 16.3.4. Shenzhen Mindray Bio-Medical Electronics Co Ltd
  • 16.3.5. FUJIFILM Holdings Corporation
  • 16.3.6. Hologic Inc.
  • 16.3.7. Canon Medical Systems Corporation
  • 16.3.8. Shenzhen Anke High-tech Co., Ltd
  • 16.3.9. Shanghai United Imaging Healthcare Co., Ltd.
  • 16.3.10. Neusoft Medical Systems Co. Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer